Factors associated with mortality in hospitalized cardiovascular disease patients infected with COVID-19.

INTRODUCTION: To reduce mortality in hospitalized patients with COVID-19 and cardiovascular disease (CVD), it is necessary to understand the relationship between patient's symptoms, risk factors, and comorbidities with their mortality rate. To the best of our knowledge, this paper is the first which take into account the determinants like risk factors, symptoms, and comorbidities leading to mortality in CVD patients who are hospitalized with COVID-19. METHODS: This study was conducted on 660 hospitalized patients with CVD and COVID-19 recruited between January 2020 and January 2021 in Iran. All patients were diagnosed with the previous history of CVD like angina, myocardial infarction, heart failure, cardiomyopathy, abnormal heart rhythms, and congenital heart disease before they were hospitalized for COVID-19. We collected data on patient's signs and symptoms, clinical and paraclinical examinations, and any underlying comorbidities. t test was used to determine the significant difference between the two deceased and alive groups. In addition, the relation between pairs of symptoms and pairs of comorbidities has been determined via correlation computation. RESULTS: Our findings suggest that signs and symptoms such as fever, cough, myalgia, chest pain, chills, abdominal pain, nausea, vomiting, diarrhea, and anorexia had no impact on patients' mortality. There was a significant correlation between COVID-19 cardiovascular patients' mortality rate and symptoms such as headache, loss of consciousness (LOC), oxygen saturation less than 93%, and need for mechanical ventilation. CONCLUSIONS: Our results might help physicians identify early symptoms, comorbidities, and risk factors related to mortality in CVD patients hospitalized for COVID-19.

Quantification of Left Ventricle Function in Stress Echocardiography Using Endocardial Area Centroid Trajectory.

Coronary artery occlusion has a direct effect on cardiac activity and is a well-known reason for ventricular motion disorder, specifically left ventricle (LV) wall motion dysfunction. In stress echocardiography, wall motion abnormality is exaggerated when stress is applied to the heart, and therefore, it is easier to diagnose abnormality in ventricular motion. In this study, we have presented a new parameter that measures LV function. We have shown that LV function can be measured using a variation of endocard borders during a cardiac cycle in standard stress echocardiography frames. This parameter shows a meaningful difference between ischemic and normal hearts and is calculated at different heart rates (HRs). In conclusion, ischemic hearts cannot keep up with the required increase in activity when reaching peak levels of stress.